These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33738601)

  • 1. Quantitative assessment of HCC wash-out on CT is a predictor of early complete response to TACE.
    Fronda M; Doriguzzi Breatta A; Gatti M; Calandri M; Maglia C; Bergamasco L; Righi D; Faletti R; Fonio P
    Eur Radiol; 2021 Sep; 31(9):6578-6588. PubMed ID: 33738601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?
    Müller L; Hahn F; Jungmann F; Mähringer-Kunz A; Stoehr F; Halfmann MC; Pinto Dos Santos D; Hinrichs J; Auer TA; Düber C; Kloeckner R
    Cancer Imaging; 2022 Jan; 22(1):5. PubMed ID: 35016731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
    Kloth C; Thaiss WM; Kärgel R; Grimmer R; Fritz J; Ioanoviciu SD; Ketelsen D; Nikolaou K; Horger M
    Acad Radiol; 2017 Nov; 24(11):1352-1363. PubMed ID: 28652049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response prediction of hepatocellular carcinoma undergoing transcatheter arterial chemoembolization: unlocking the potential of CT texture analysis through nested decision tree models.
    Vosshenrich J; Zech CJ; Heye T; Boldanova T; Fucile G; Wieland S; Heim MH; Boll DT
    Eur Radiol; 2021 Jun; 31(6):4367-4376. PubMed ID: 33274405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative analysis with multiphase contrast-enhanced computed tomography to evaluate residual tumor activity of hepatocellular carcinoma after DEB-TACE.
    Hu W; Cao G; Ye S; Xu J; Chen J; Shao G
    Medicine (Baltimore); 2023 Jun; 102(24):e34054. PubMed ID: 37327303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Immediate Post-Procedural Cone-Beam Computed Tomography (CBCT) in Predicting the Early Radiologic Response of Hepatocellular Carcinoma (HCC) Nodules to Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE).
    Fronda M; Mistretta F; Calandri M; Ciferri F; Nardelli F; Bergamasco L; Fonio P; Doriguzzi Breatta A
    J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parenchymal Blood Volume Assessed by C-Arm-Based Computed Tomography in Immediate Posttreatment Evaluation of Drug-Eluting Bead Transarterial Chemoembolization in Hepatocellular Carcinoma.
    Syha R; Grözinger G; Grosse U; Maurer M; Zender L; Horger M; Nikolaou K; Ketelsen D
    Invest Radiol; 2016 Feb; 51(2):121-6. PubMed ID: 26488373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma.
    Vesselle G; Quirier-Leleu C; Velasco S; Charier F; Silvain C; Boucebci S; Ingrand P; Tasu JP
    Eur Radiol; 2016 Jun; 26(6):1640-8. PubMed ID: 26455721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
    Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
    AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
    [No Abstract]   [Full Text] [Related]  

  • 10. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
    Habbel VSA; Zeile M; Stavrou GA; Wacker F; Brüning R; Oldhafer KJ; Rodt T
    Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Enhancement and Heterogeneity Are Associated With Treatment Response to Drug-Eluting Bead Chemoembolization for Hepatocellular Carcinoma.
    Reis SP; Sutphin PD; Singal AG; Grzybowski R; Fisher S; Ball C; Xi Y; Grewal S; Kalva SP
    J Comput Assist Tomogr; 2017; 41(2):289-293. PubMed ID: 27824665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.
    Nicolini D; Agostini A; Montalti R; Mocchegiani F; Mincarelli C; Mandolesi A; Robertson NL; Candelari R; Giovagnoni A; Vivarelli M
    World J Gastroenterol; 2017 May; 23(20):3690-3701. PubMed ID: 28611522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of Therapeutic Response of Hepatocellular Carcinoma to Transcatheter Arterial Chemoembolization Based on Pretherapeutic Dynamic CT and Textural Findings.
    Park HJ; Kim JH; Choi SY; Lee ES; Park SJ; Byun JY; Choi BI
    AJR Am J Roentgenol; 2017 Oct; 209(4):W211-W220. PubMed ID: 28813195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization.
    Choi MH; Park GE; Oh SN; Park MY; Rha SE; Lee YJ; Jung SE; Choi JI
    Acad Radiol; 2018 Nov; 25(11):1363-1373. PubMed ID: 29555570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computed tomographic perfusion with 160-mm coverage: comparative analysis of hepatocellular carcinoma treated by two transarterial chemoembolization courses relative to magnetic resonance imaging findings.
    Bayle M; Clerc-Urmès I; Ayav A; Bronowicki JP; Petit I; Orry X; Laurent V
    Abdom Radiol (NY); 2019 Jan; 44(1):85-94. PubMed ID: 30054686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of contrast-enhanced ultrasound and contrast-enhanced computed tomography in evaluating the treatment response to transcatheter arterial chemoembolization of hepatocellular carcinoma using modified RECIST.
    Liu M; Lin MX; Lu MD; Xu ZF; Zheng KG; Wang W; Kuang M; Zhuang WQ; Xie XY
    Eur Radiol; 2015 Aug; 25(8):2502-11. PubMed ID: 25702094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE.
    Schobert IT; Savic LJ; Chapiro J; Bousabarah K; Chen E; Laage-Gaupp F; Tefera J; Nezami N; Lin M; Pollak J; Schlachter T
    Eur Radiol; 2020 Oct; 30(10):5663-5673. PubMed ID: 32424595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apparent Diffusion Coefficient as a Noninvasive Biomarker for the Early Response in Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Using Drug-eluting Beads.
    Li B; Zhou L; Xu A; Li Q; Xiang H; Huang Y; Peng L; Xiang K; Zhang M; Wang N
    Curr Med Imaging; 2022; 18(11):1186-1194. PubMed ID: 35249499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
    Li J; Wang N; Shi C; Liu Q; Song J; Ye X
    J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-dimensional parametric parenchymal blood flow in transarterial chemoembolisation for hepatocellular carcinoma: perfusion change quantification and tumour response prediction at 3 months post-intervention.
    Becker LS; Maschke SK; Dewald CLA; Meine TC; Winther HBM; Kirstein MM; Kloeckner R; Meyer BC; Wacker F; Hinrichs JB
    Clin Radiol; 2021 Feb; 76(2):160.e27-160.e33. PubMed ID: 33028487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.